Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

150
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
150
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

204
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
204
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

161
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
161
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

159
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
159
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

228
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
228

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Future of Psoriasis Care.

Cutis·2026
Same author

Letter From the New Editor-in-Chief.

Journal of psoriasis and psoriatic arthritis·2026
Same author

Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence.

Journal of drugs in dermatology : JDD·2026
Same author

More Than Skin Clearance: Connecting Brodalumab's Mechanism of Action to Patient Outcomes in Psoriasis.

Journal of drugs in dermatology : JDD·2025
Same author

The Role of Simultaneous Janus Kinase Inhibitor and Biologic Therapy Use for Refractory Atopic Dermatitis.

Journal of drugs in dermatology : JDD·2025
Same author

IL-17C as a Driver of Inflammation in Psoriasis.

Advances in therapy·2025

Related Experiment Video

Updated: Jul 27, 2025

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

435

Biologic Vs Conventional Therapies: Comparing Risk of Psoriasis-Associated Comorbidities.

Evan Darwin, Mark Lebwohl, George Han

    Journal of Drugs in Dermatology : JDD
    |June 5, 2023
    PubMed
    Summary

    Psoriasis patients receiving biologic treatments showed fewer comorbidities than those on conventional therapy. This study suggests biologics may offer better management of associated health conditions in psoriasis care.

    More Related Videos

    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
    11:39

    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

    Published on: July 11, 2013

    39.0K
    Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
    06:37

    Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

    Published on: September 15, 2023

    672

    Related Experiment Videos

    Last Updated: Jul 27, 2025

    Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
    02:28

    Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

    Published on: March 1, 2024

    435
    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
    11:39

    The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

    Published on: July 11, 2013

    39.0K
    Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
    06:37

    Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

    Published on: September 15, 2023

    672

    Area of Science:

    • Dermatology
    • Clinical Immunology
    • Epidemiology

    Background:

    • Psoriasis is a chronic inflammatory condition linked to numerous comorbidities.
    • Understanding the impact of different treatment modalities on these comorbidities is crucial for comprehensive patient care.

    Purpose of the Study:

    • To compare the prevalence of comorbidities in psoriasis patients treated with biologic therapies versus conventional treatments.
    • To evaluate the potential association between biologic treatments and reduced comorbidity rates.

    Main Methods:

    • Retrospective cohort analysis of patients with psoriasis.
    • Comparison of comorbidity data between patients receiving biologic treatments and those on conventional therapies.

    Main Results:

    • Patients treated with biologic therapies exhibited lower rates of comorbidities compared to those on conventional treatments.
    • The data suggests a potential benefit of biologics in managing psoriasis-associated health conditions.

    Conclusions:

    • Biologic treatments may be associated with a reduced burden of comorbidities in patients with psoriasis.
    • Further research is warranted to confirm these findings and elucidate the mechanisms involved.